NEW YORK, Nov. 29, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of Amicus Therapeutics, Inc. ("Amicus" or the "Company")
(NASDAQ: FOLD). Such investors can obtain additional information
and assist the investigation by visiting the firm's site:
www.bgandg.com/fold.
The investigation concerns whether Amicus and certain of its
officers and/or directors have violated Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.
On November 28, 2016, Amicus
announced that the United States Food and Drug Administration will
not grant an accelerated approval for its drug migalastat to treat
Fabry disease. Following this news, Amicus stock dropped over 21%
on intraday trading on November 29,
2016.
If you are aware of any facts relating to this investigation, or
purchased Amicus shares, you can assist this investigation by
visiting the firm's site: www.bgandg.com/fold. You can also
contact Peretz Bronstein or his
Investor Relations Analyst, Yael
Hurwitz of Bronstein, Gewirtz & Grossman, LLC:
212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
Logo - http://photos.prnewswire.com/prnh/20161114/439152LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-amicus-therapeutics-inc-fold-300370028.html
SOURCE Bronstein, Gewirtz & Grossman, LLC